Seeking Alpha
12 Nov 2026, 07:31 UTC · 1h ago
Ultragenyx: Gene Therapies Must Show, Not Tell, Initiating Hold
Impact · against what's priced in
The article provides no new catalyst for RARE, as its primary claims regarding pipeline failures, cash runway, and profitability targets are already reflected in the current valuation. The initiation of a 'Hold' rating confirms the market's current skepticism rather than challenging it.
- RARE+0.00
Already priced in
- The price assumes
The reality that the Phase 3 trial for GTX-102 in Angelman syndrome failed, erasing most of the stock's prior premium.
The analyst's view that late-stage pipeline failures have reset investor sentiment aligns with the market's current rejection of bullish analyst models.
What RARE's price assumes · Sep 22
Top 1 mover · tap to explore
